Annual Reports/DSUR/PSUR Featured Articles

1. Speeding Research With Data Mining Expertise 4/26/2016

   According to The STM Report (2015), more than 2.5 million peer-reviewed articles are published in scholarly journals each year. PubMed alone contains more than 25 million citations for biomedical journal articles from MEDLINE. The amount and availability of content for clinical researchers has never been greater – but finding the right articles to use is becoming more difficult.

2. Pharmacovigilance Trends: Getting To Know The DSUR 4/15/2013

   In 2010, the International Conference on Harmonization (ICH) rolled out its E2F Development Safety Update Report (DSUR) guideline. The DSUR is similar to the US’s Investigational New Drug Annual Report (IND-AR) and the EU’s Annual Safety Report (ASR) in that its purpose is to provide a brief overview of safety for a project on an annual basis. By Malarkodi S. Moorthy, M.Sc., M.Phil., Medical Writer

3. Economic Freedom And Innovation – Why We Should All Be Worried 4/15/2013

   Are you concerned about the ranking of the United States in regard to the Economic Freedom of the World Annual Report? If not, you should be – and here’s why. Economic freedom is not just about politics or tariffs or regulations. It is about people. It is about being able to work where you want, when you want, trade the way you want, and live in a society where you are protected from others. It is also about the level of your health and your life expectancy.

4. Ever Think About Outsourcing Your Drug Safety Challenges? 4/17/2012

   Pharmacovigilance is the science relating to the detection, assessment, understanding and prevention of adverse effects of medications and medical devices. At a recent conference, Sentrx’ CEO, Michael O’Gorman, sat down with Clinical Leader to answer some questions on some of the trends taking place in the pharmaceutical and biotech industry in the area of pharmacovigilance. His experience as a leader for several technology-focused organizations, as well as his having worked as a consultant with KPMG provide him with a unique perspective on pharmaceutical industry trends, especially when it comes to drug safety.By Rob Wright, Chief Editor, Life Science Leader magazine